[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"estrogen-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:estrogen-deficiency":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,81,108,139,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100638924","atenea-study-adherence-to-creatine-based-nutritional-supplementation-in-estrogen-depleted-women-100638924",false,"NCT07580846","ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women","AssessmenT of thE Adherence of Nutritional Supplementation With Creatine Formula in Estrogen-Depleted Adult Women: Prospective Clinical Investigation","ATENEA","Inclusion Criteria:\n\n* Biological female sex.\n* Age ≥40 years.\n* Estrogen-depleted status, defined as at least one of the following:\n\nnatural menopause, defined as amenorrhea for ≥12 consecutive months; surgically induced menopause; late perimenopause with elevated FSH according to clinical judgment.\n\n* Absence of major comorbidities that would contraindicate use of the nutritional supplement or the recommended physical activity.\n* No relevant changes in usual treatment during the previous 3 months.\n* Ability to understand the study information and provide written informed consent.\n* Willingness to take the nutritional supplement according to the study instructions.\n* Willingness to follow general physical activity recommendations provided by the investigator.\n* Willingness and ability to attend the planned visits and complete study assessments through Week 12.\n\nExclusion Criteria:\n\n* Initiation or modification of treatment with GLP-1 receptor agonists within the previous 12 weeks.\n* Presence of musculoskeletal or joint conditions that significantly limit the ability to perform regular physical activity or study-related functional assessments.\n* Clinically relevant renal or hepatic disease.\n* Current use of diuretics or potentially nephrotoxic medications.\n* Known allergy or intolerance to any component of the nutritional supplement.\n* Participation in another clinical study (nutritional, pharmacological, or interventional) within the previous 3 months.\n* Any medical condition or social circumstance that, in the investigator's judgment, could interfere with study participation, adherence, or data validity.",true,"FEMALE","40 Years","75 Years",{"count":22,"type":23},100,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, observational clinical study conducted under routine clinical practice conditions aimed at describing adherence to a creatine-based nutritional supplement (Creaticare FEM) in estrogen-depleted adult women. Participants will receive the supplement for 12 weeks, and adherence will be assessed as the percentage of doses consumed and the proportion of participants achieving ≥80% adherence. Secondary outcomes include persistence, satisfaction, tolerability, and adherence to recommended physical activity. Exploratory outcomes include changes in muscle strength, body composition, quality of life, joint pain, and skin health.",[27,28],"Menopause","Estrogen Deficiency",[30,27,31,32,33,34],"Creatine","Women´s Health","Estrogen deficiency","Collagen","Dietary supplements","RECRUITING","2026-05-05",{"date":38,"type":39},"2026-05-12","ACTUAL",{"date":41,"type":39},"2026-03-20",{"date":43,"type":23},"2026-10-01",{"name":45,"class":46},"Margan Biotech","INDUSTRY",4,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100542515","phase-3-estradiol-and-testosterone-subdermal-implants-for-menopause-treatment-estime-100542515","NCT06343870","Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)","Pharmacokinetic, Clinical, Hormonal and Therapeutic Effects of the Use of Estradiol and Testosterone Hormonal Subdermal Implants in Women With Natural Menopause, Premature Ovarian Failure or Surgical Menopause Due to Cervical Cancer.","ESTIME","Inclusion Criteria:\n\n* menopause time of 2 to 6 years;\n* Body Mass Index between 25 and 30 kg\u002Fm2;\n* women hysterectomized and ovariectomized due to cervical cancer;\n* women with premature ovarian failure and under 40 years of age;\n* active sex life;\n* absence of severe depression and anxiety, confirmed by evaluation using the Beck (specific for depression) and Beck (specific for anxiety) questionnaires.\n\nExclusion Criteria:\n\n* disabling illnesses;\n* use of medications that inhibit sexual desire;\n* inability to answer the questionnaires;\n* altered routine exams and comorbidities:\n\n  * Severe hypertension with Blood Pressure measurement \\> 160 x 90 mmHg in two measurements\n  * clinical or subclinical thyroid dysfunction with Thyroid-stimulating hormone \\> 4 mIU\u002FL\n  * dyslipidemia - fasting triglyceride level \\> 400 mg\u002FdL\n  * presence of occult blood in feces\n  * hyperprolactinemia (\\>29ng\u002FmL)\n  * fasting blood glucose \\> 100 mg\u002FdL\n  * presence of osteopenia or osteoporosis\n  * BIRADS classification greater than or equal to 3 on mammography\n  * presence of endometrial echo \\> 4mm on transvaginal ultrasound\n  * presence of changes in oncotic colpocytology\n* diagnosis after psychological screening of moderate to severe anxiety\u002Fdepression.","18 Years","60 Years",{"count":59,"type":23},140,"INTERVENTIONAL",[62],"PHASE3","Estrogen and androgen deficiencies negatively impact the quality of life of women at different stages of life, especially after menopause. New modalities and new therapeutic alternatives have been researched. Parenteral administration of estradiol and testosterone could be effective to treat symptoms secondary to estrogen and androgen deficiencies and minimize these adverse events. This study evaluates the efficiency of subdermal implant-bioabsorbable use in women with menopausal symptoms associated with secondary estrogen and androgen deficiencies in women with natural menopause, premature ovarian failure or surgical menopause due to cervical cancer. Pharmacokinetic, biochemical, metabolic, thromboembolic and hormonal data will be evaluated, as well as the effects on quality of life, menopausal symptoms and sexual function after treatment.",[27,65,28],"Testosterone Deficiency",[67,68,69],"menopause","estrogen","testosterone","2025-12-20",{"date":72,"type":39},"2025-12-29",{"date":74,"type":39},"2025-12-18",{"date":76,"type":23},"2027-04-30",{"name":78,"class":79},"University of Sao Paulo General Hospital","OTHER",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":17,"sex":89,"minAge":56,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":80},"100570920","investigating-oestrogen-signalling-and-the-effect-upon-the-extracelluar-matrix-in-patients-with-obstructive-lung-disease-100570920","NCT06713512","InvEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease","invEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease","ESSENTIAL","Inclusion Criteria:\n\n1. Men and women aged \\> 18 years.\n2. For female participants: pre-menopausal, peri-menopausal and post-menopausal women can all be included.\n3. Participants willing and able to give informed consent for participation in the study.\n4. Healthy controls \\<10 pack year history (participants without Asthma or COPD).\n\nExclusion Criteria:\n\n1. Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.\n2. Alcohol or recreational drug abuse, is defined as when the use is harmful as per NHS definition.\n3. History of psychiatric, medical, or surgical disorders.\n4. Pregnant\n5. Unable to provide written informed consent\n6. History of advanced medical conditions with an expected prognosis of \\< 3 years.\n7. Patients with a history of active cancer.\n8. Patients on long term oxygen (ambulatory oxygen).","ALL","99 Years",{"count":22,"type":23},"This study aims to understand the role of oestrogen in patients with asthma and Chronic Obstructive Pulmonary Disorder (COPD). Therefore, what is the effect of oestrogen in these participants compared to controls (those without disease). The study hypothesises that oestrogen loss in patients with asthma and COPD causes accelerated lung function decline and changes to lung structure. It will investigate if this is mediated by inflammation, immune host response or elastin and collagen changes. It is an observational prospective cohort study aiming to recruit healthy controls, and people with asthma or COPD), and\u002For the menopause.",[94,95,28,96],"Chronic Obstructive Lung Disease","Respiratory Ilness","Asthma",[96,98],"COPD","2024-11-27",{"date":101,"type":39},"2024-12-03",{"date":103,"type":23},"2024-12-01",{"date":105,"type":23},"2028-11-01",{"name":107,"class":79},"Guy's and St Thomas' NHS Foundation Trust",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":60,"phases":118,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":80},"100557927","phase-4-determining-dose-equivalence-between-oral-and-transdermal-estrogen-treatment-in-women-with-turner-syndrome-100557927","NCT06544473","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome - A Randomized Study","Inclusion Criteria:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nExclusion Criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy","50 Years",{"count":117,"type":23},50,[119],"PHASE4","This 5-week, phase IV randomized crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The objective is to establish the equipotency between the two estradiol regimens by evaluating various estradiol-dependent surrogate markers. The study involves 50 women with TS, aged 18-50 years, who are randomized to receive either oral or transdermal ERT for 14 days, followed by a crossover to the alternate treatment for another 14 days, with a one-week washout period in between. Blood tests are conducted at baseline, after the first 14 days of treatment, after the washout period, and after the final 14 days of treatment. The investigators anticipate that this study will provide clinicians with a better understanding of ERT in treating women with TS.",[122,123,124,125,28],"Turner Syndrome","Hypogonadism; Ovarian","Hormone Replacement Therapy","Estrogen Replacement Therapy",[127,124,125,128,129],"Turner syndrome","Estrogen treatment","Dose equipotency","2024-08-22",{"date":132,"type":39},"2024-08-23",{"date":134,"type":39},"2021-11-29",{"date":136,"type":23},"2026-12-31",{"name":138,"class":79},"Aarhus University Hospital",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":115,"enrollmentInfo":146,"targetDuration":4,"studyType":60,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":158,"locationsCount":80},"100559924","phase-4-long-term-effects-of-oral-versus-transdermal-estrogen-replacement-therapy-in-turner-syndrome-100559924","NCT06570460","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome - A Randomized Trial","Inclusion criteria:\n\nFor participants with TS:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nFor healthy controls:\n\n* Female\n* Age 18-50 years\n* Previously healthy\n* Not receiving any medication\n* Not using any form of contraceptive pills\n* No mental or psychiatric disorders\n\nExclusion criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy\n* Menopause (for the control group only)",{"count":117,"type":23},[119],"This 14-month, phase IV, randomized controlled crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The study's objectives are to clarify endocrine, metabolic, cardiovascular, and thromboembolic risk factors in TS after a wash-out period without estrogen (E2) treatment; compare the effects of oral versus transdermal (TD) ERT regimens; and examine the long-term effects of E2 administration via these two routes. The study involves 50 TS women aged 18-50 years and 50 control participants. TS participants are randomized to receive either oral or TD ERT for six months, followed by crossover to the alternate treatment for another six months. Prior to randomization, any existing ERT will be discontinued for a 1-month washout period. A second 1-month washout period will occur between the two 6-month treatment phases. Laboratory analyses and clinical investigations are performed after the first wash-out period, after the first six months of treatment, and after the last six months of treatment. We anticipate that this study may provide a basis for new and improved recommendations for sex hormone replacement therapy in TS.",[122,123,124,125,28],[127,151,152,128,153],"Hormone replacement therapy","Estrogen replacement therapy","Long term side effects",{"date":155,"type":39},"2024-08-26",{"date":134,"type":39},{"date":136,"type":23},{"name":138,"class":79},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":17,"sex":18,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":60,"phases":169,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":80},"100536442","phase-4-cardiometabolic-consequences-of-the-loss-of-ovarian-function-100536442","NCT06264882","Cardiometabolic Consequences of the Loss of Ovarian Function","LILAC","Inclusion Criteria:\n\n* Age criteria of 20-45 years: the investigators are determining the effects of ovarian suppression on adiposity and vascular in premenopausal women;\n* Premenopausal defined as normal menstrual cycle function defined as no more than 1 missed cycle in the previous year: irregular menstrual or missed menstrual cycles could indicate that women are anovulatory and\u002For perimenopause;\n* Not pregnant or planning to become pregnant;\n* Not lactating in the last 3 months;\n* Serum FSH \\\u003C10 IU\u002FL measured during days 1-10 of the menstrual cycle: to ensure the woman is premenopausal and not perimenopausal;\n* Not on hormonal contraception in the last 3 months;\n* Sedentary or recreationally active (\\\u003C2 days\u002Fwk vigorous exercise);\n* No use of medications that might influence vascular function (i.e., antihypertensives, lipid lowering medications, blood thinners);\n* No use of antioxidant supplements or chronic NSAIDs or be willing to go off them for 4 weeks prior to enrollment in the study;\n\nExclusion Criteria:\n\n* Diabetic or fasted glucose \\>126 mg\u002FdL;\n* Body mass index (BMI) \\>35 kg\u002Fm2;\n* Weight change \\>5 kg in the last 3 months;\n* Use of glucocorticoids (inhaled, oral, topical) or drugs that affect glucocorticoid metabolism (e.g., ketoconazole) in the last 3 months;\n* Excess alcohol consumption, defined as \\>14 drinks per week by self-report;\n* Known hypersensitivity to study medications;\n* Depressive symptoms, defined as a CES-D score \\>16;\n* Resting blood pressure \\>150\u002F90 mmHg;\n* Preexisting or active cardiac, renal, or hepatic disease: past or current history of these diseases or conditions;\n* Active or chronic infection: inflammation associated with active or chronic infections impair vascular function;\n* Thyroid dysfunction, defined as an ultrasensitive TSH \\\u003C0.5 or \\>5.0 mU\u002FL; volunteers with abnormal TSH values will be reconsidered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;\n* Smoking or Tobacco use within the previous 12 months;\n* Severe low bone mass or osteoporosis, defined as a hip or lumbar spine T-score \\\u003C-2.0: safety reasons, women who are randomized to the ovarian suppression plus placebo group could see a decrease in bone mineral density due to the suppression of estrogen;\n* History of venous thromboembolic event (VTE): safety reasons, estradiol therapy can increase the risk of VTE;\n* History of breast cancer or other estrogen-dependent neoplasm: estradiol therapy is contraindicated;","20 Years","45 Years",{"count":22,"type":23},[119],"The menopause transition is associated with a decrease in artery health and an increased risk for weight gain in storing fat in the stomach area which may increase the risk for heart disease. The purpose of this research is to study how the decrease in estrogen at menopause changes artery health and fat gain, and risk of disease in women as they age. The first aim in this study will determine whether short term and long term low estrogen levels in premenopausal women decreases artery function and whether this is related to an increase in fat in the stomach area. The second aim will determine whether the changes in artery health and body fat are related to changes in a pathway that breaks down an important amino acid called tryptophan. This pathway is thought to play a role in regulating the aging process. Therefore, the investigators will determine whether the decrease in artery health and the increase in body fat in the stomach region with low estrogen is related to changes in this pathway in the blood, in vascular cells and fat tissue. Because estrogen levels fluctuate in premenopausal women, the investigators will use an approach (intervention) that controls estrogen levels to address these aims. The investigators will use a medication that is typically used to treat endometriosis or uterine fibroids to lower estrogen levels and an estrogen patch to increase estrogen in some women. Some women will receive a patch that has no estrogen (called a placebo patch). The intervention period will be 20 weeks. The study will provide us with new knowledge on how low estrogen with menopause affects artery health and fat gain estrogen.",[27,28,172,173],"Aging","Adiposity",[175,176,177],"Vascular biology","Women's health","Women","2024-06-18",{"date":180,"type":39},"2024-06-20",{"date":182,"type":39},"2024-06-01",{"date":184,"type":23},"2028-08-31",{"name":186,"class":79},"University of Colorado, Denver"]